/* Template Name: NBN - Single Page */
The European Prevention of Alzheimers Dementia Consortium (EPAD) meet on a yearly basis. This year, NBN founder Miia Kivipelto had the pleasure of hosting the meeting in Stockholm, including around 150 attendees.
Her Majesty Queen Silvia of Sweden opened the meeting and also the CEO of Karolinska University Hospital, Melvin Samsom.
On April 21st we gathered, together with the team from KTH, at Balingsholms Kursgård outside of Stockholm for a 2 day retreat to discuss and plan the EACare project. There were some very interesting and good discussions.
Please visit EACare for more information.
NBN founder, Prof. Miia Kivipelto and member Dr Krister Håkansson has written an article for the longest continuously published magazine in the US, the very wellknown Scientific American. The article was published in the April 2017 issue (volume 316, number 4) and ended up on the front page!
For 30 years MetLife Foundation has presented prestigious awards to outstanding researchers in the field of Alzheimer’s disease. This year, MetLife Foundation presented Miia Kivipelto as one of the awardees for the Major Award, giving her an institutional grant of $100,000 .
“MetLife Foundation is proud to present the Major Awards to Dr. Bu and Dr. Kivipelto for their exceptional scientific research contributions, which help bring us closer to finding a cure for Alzheimer’s disease and related dementias,” notes A. Dennis White, President and Chief Executive Officer, MetLife Foundation. “Their outstanding contributions, recognized around the world, have helped us better understand this devastating illness, and both awardees have laid the groundwork leading to effective treatments.”
The awardees are selected by an expert advisory committee, led by chair David. M. Holtzman, M.D., the Andrew B. and Gretchen P. Jones Professor and chairman, Department of Neurology, Washington University School of Medicine in St. Louis Missouri. Dr. Holtzman received a Major Award from MetLife Foundation in 2006.
The awards are administered by the American Federation for Aging Research, who manages the award selection process and expert committee as well as the awards presentation.
“These four individuals have performed groundbreaking work, and the awards will help further their pioneering research,” noted Dr. Holtzman. “Drs. Bu, Kivipelto, Slutsky, and Cirrito join a roster of past winners whose work has gone onto receive recognition in the field and beyond, including the Nobel Prize, the Potamkin Prize, and TIME Magazine’s scientist of the year. MetLife Foundation has an outstanding track record of recognizing talent whose research has sparked or advanced major research paradigms.”
Promising Investigator Awards:
Learn more about past awardees at http://mlfawards.afar.org
Learn more about MetLife Foundation https://www.metlife.com/metlife-foundation/index.html
Learn more about AFAR http://www.afar.org.
Professor Kivipelto has been appointed an individual funding of 15 million SEK from Wallenberg Clinical Scholar 2016.Miia Kivipelto has made significant contributions to insights into how the development of dementia can be slowed down through the use of lifestyle measures. As a Wallenberg Clinical Scholar she will build a platform for clinical trials and continue to investigate treatments that can help people with dementia to keep their memories for longer.Globally, the frequency of Alzheimer’s disease and other dementias is rapidly increasing. In recent decades, a great deal of resources have been put in to developing pharmaceuticals that can prevent the progress of the disease, but this has turned out to be easier said than done. As yet there is no drugs that can prevent the development of dementia.However, Miia Kivipelto has shown that it is possible to decrease memory problems with a number of measures: changed diet, physical training, cognitive training and normalising blood pressure and blood lipids.As a Wallenberg Clinical Scholar, Miia Kivipelto will continue to investigate how best to prevent the disease. Among other things, she will develop a platform for high-quality clinical studies of dementia. Her work also includes developing models for assessing a person’s risk of dementia, investigating which mechanisms drive the disease and how these can be counteracted through a range of measures.
The Knut and Alice Wallenberg Foundation (KAW) is one of the largest private financiers of research in Europe. The Foundation grants currently the total of SEK 1.7 billion per year for various projects, mainly at Swedish Universities. KAW grants funding in two main areas; research projects of high scientific potential and individual support of excellent scientists. The funding goes mainly to research within the natural sciences, technology and medicine. The Wallenberg Clinical Scholars programme is managed in collaboration with the Royal Swedish Academy of Sciences (KVA).
Miia Kivipelto tilldelas Alzheimerfondens stora forskningspris som uppgår till 2,5 miljoner kronor.- Jag är jätteglad och tacksam. Det är en ära och ett erkännande att det vi gör är viktigt. Det innebär att vi snabbare kan gå från forskning till implementering. Förhoppningsvis kan vi redan i år gå ut med konkreta råd och riktlinjer för hur man genom särskild kosthållning och ökad fysisk aktivitet kan förebygga risken att drabbas av minnesstörningar, säger Miia Kivipelto.För att läsa en längre intervju och mer om priset, gå in på Alzheimerfondens sida: http://www.alzheimerfonden.se/aktuellt/alzheimerfondens-stora-forskningspris-jan2016
Foto: Johan Gunséus
Den 17 oktober mottar professor Kivipelto priset för sin forskning inom minnessjukdomar och förebyggande åtgärder. Ceremonin hålls vid Umeå universitets årshögtid, där även Kung Carl XVI Gustaf närvarar.